Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Parkinson Disease Clinical Trial

Official title: Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease - Phase 1

Status Withdrawn

Clinical Trial Summary

The purpose of this research study is to determine optimum dose of vibration delivered by an experimental device called PDVibe2 required to treat freezing of gait in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.

Clinical Trial Description

Participation will require up to 8 treatment sessions within 5 days (no more than 2 sessions in one day) plus an additional day for screening and another for follow-up (7 days total). All visits will occur at the Virginia Commonwealth University Parkinson's Movement and Disorders Center in Richmond, VA. Participants will be asked to walk for a brief period of time while wearing the PDVibe2. The PDVibe2 will provide vibration therapy and study staff will measure the number of "freezes" before, during and after therapy. Participants will be asked to provide feedback on the device, the therapy session and how they are feeling. ;

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT03872115
• Study type: Interventional
• Source: Virginia Commonwealth University
• Status: Withdrawn
• Phase: N/A
• Start date: April 18, 2019
• Completion date: April 2020